Latest News

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.
Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer

October 17th 2024

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer

October 10th 2024

Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.
Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC

October 9th 2024

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.
Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer

October 6th 2024

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.
Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer

October 3rd 2024

More News